RxDoctor Payments Data

Tara Becker, MD

Neurology · West Palm Beach, FLNPI 1598119398

Payments from drug & device makers

$12,025in general payments, 2019–2025

Across 460 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AbbVie$1K
  • Livanova USA, Inc.$1K
  • Neurelis, Inc.$1K
  • MDD US Operations, LLC$744
  • Eisai Inc.$642
  • plus $6K from 42 others

What the payments were for

  • Travel & lodging$5815%
  • Food & beverage$11,42795%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,025 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$270,119
Medicare patients
350
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant68$120,681
Nurtec OdtRimegepant Sulfate64$113,633
QuliptaAtogepant66$88,795
BriviactBrivaracetam29$44,365
NayzilamMidazolam26$27,637
LamictalLamotrigine16$22,763
VimpatLacosamide17$22,310
Lacosamide159$18,913
Levetiracetam340$9,596
Lamotrigine ErLamotrigine27$8,260
Memantine Hcl263$6,815
Carbamazepine ErCarbamazepine54$5,231
Donepezil Hcl394$4,262
Lamotrigine230$4,203
Oxcarbazepine12$3,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,218$209,476134 claims
PfizerNurtec Odt$440$113,63364 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$1,327$94,31172 claims
Upsher-smith Laboratories LLCTopiramate$166$83771 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →